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Abstract
Background: Men who have sex with men (MSM) now account for nearly half of all new HIV
cases in Malaysia. There has been little research, however, characterizing the HIV care
continuum among MSM living with HIV in Malaysia. This study describes the HIV care
continuum and examines factors associated with HIV viral non-suppression among newly
diagnosed MSM living with HIV in Kuala Lumpur, Malaysia.
Methods: We enrolled 163 MSM living with HIV who were in care at a major university hospital
in Kuala Lumpur, Malaysia. Participants completed a self-administered questionnaire. Electronic
medical chart review also provided data on engagement in the care continuum, including CD4
counts and HIV viral loads. Bivariate and multivariable logistic regression was used to identify
correlates of HIV viral non-suppression.
Results: 94.4% of this sample is currently on ART while 79.7% self-reported 100% adherence to
medication. Nearly 80% of this population were optimally virally suppressed at <20 copies/mL.
In the multivariable model, not having a full-time job (aOR = 6.25; 95% CI = 1.53 – 25.49; p =
0.011) and being single (aOR = 9.15; CI = 1.07 – 78.21; p = 0.043) were associated with viral
non-suppression (viral load of 200 copies/mL or more). 9.8% of all participants reported active
(last 30 days) chemsex participation while nearly 40% indicated severe depression symptoms.
Conclusions: This is the first study to describe the HIV care continuum on MSM from Malaysia.
Though many MSM in this sample were able to achieve viral suppression, others continue to
face socioeconomic barriers to treatment and retention in care. Future studies should recruit from
a wider range of venues and include those disengaged from care.
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Background
HIV in men who have sex with men
Globally, men who have sex with men (MSM) have been disproportionately affected by HIV.1
Although AIDS-related mortality has gradually declined over the last decade,2 many countries
are experiencing re-emergent epidemics driven by sexual transmission, particularly among
MSM.3 In several high-income Western European countries, Australia and the United States,
HIV infection rates in the general population decreased, but not in MSM.4 In some low- and
middle-income settings like Ghana and Peru, MSM were the predominant contributor to HIV.5 In
the Asia-Pacific region, over 75% of new HIV infections in 2018 were among key populations
and their sexual partners, especially young gay men (age 15 to 24) and other young MSM.2
HIV in Malaysia
Malaysia still has one of the highest burdens of HIV in its region.2 Since the first case of HIV
was detected in the country in 1986, the total number of HIV diagnoses in Malaysia is estimated
to be 118,883 with a national adult prevalence of 0.4%.6 By the end of 2018, there were 87,041
living with HIV in Malaysia.6 The Malaysian epidemic is characterized by significant regional
variations in severity: three states – Selangor, Kuala Lumpur and Putra Jaya, and Johor –
accounted for approximately half of PWH in Malaysia.6
Historically, Malaysia’s HIV epidemic was primarily driven by people who inject drugs (PWID),
which accounted for 83% of reported cases in 1996.6 In stark contrast, new HIV infections by
sexual transmission among MSM in 1996 was 2%.6 This trend has reversed in recent years, with
sexual transmission among MSM leading 56% of new HIV infections in 2018, while new
infections among PWID declined to 3%.6
4

MSM and HIV in Malaysia
Malaysia has the second highest HIV prevalence among gay men and other MSM in the AsiaPacific region after Indonesia.2 As of 2017, 21.6% of MSM in Malaysia were estimated to be
HIV-infected, more than doubling from 8.9% three years prior.7 This trend was also seen in
Kuala Lumpur, Malaysia’s largest and most urbanized city, where prevalence increased twofold,
from 22% in 2014 to 43.3% in 2017.7 By the end of 2017, more than half (56.7%) of MSM were
unaware of their HIV status.8
This growing epidemic among MSM has been associated with several high-risk behaviors. HIVpositive MSM in Malaysia showed higher rates of unprotected anal intercourse,9,10 multiple sex
partners, and group sex.10,11 Up to 13%12 of Malaysian MSM have engaged in ‘chemsex’ at least
once in their lifetime,13 which is the use of psychoactive drugs, particularly stimulants, to
enhance sexual pleasure,13 which are significantly associated with HIV infection.14 Additionally,
those who engaged in chemsex were more likely to have multiple sex partners, engage in group
sex, show inconsistent condom use, and to have previously acquired sexually transmitted
infections (STIs).12,15 MSM have also reported high use of geosocial sexual networking phone
applications to find sex partners, which has been associated with increased engagement in
chemsex,15 reduced condom use16,17 and increased STIs.17
These findings are of concern for HIV prevention as substance abuse is likely to be part of the
overlapping health problems (‘syndemics’) that put Malaysian MSM at high risk for HIV/STI
infection and transmission.14,18-21 There are also implications for HIV treatment as alcohol and
drug use was independently associated with antiretroviral therapy (ART) treatment nonadherence.22,23 Amphetamine-type stimulants (ATS) use, particularly methamphetamine, was
more strongly linked to engagement in condomless sex than were other drugs.22 Previous
5

research has shown that alcohol and substance use by MSM as means to cope with HIV-related
stress can lead to more depressive symptoms and even cognitive impairment.23
In addition, Malaysian MSM face long-standing religious, cultural, and legal prohibitions of drug
use and homosexuality, which exacerbate the dual burden of social stigma and discrimination
and limit their access to successful and equitable delivery of existing HIV prevention efforts,
further escalating the HIV epidemic.24,25 Same-sex sexual acts are punishable by imprisonment
of 14 years to life2, institutionalizing and criminalizing homophobia at the national level. Muslim
and all ethnic Malay MSM face further stigma26 internally and externally from their families and
religious communities as homosexuality is a punishable sin under Sharia law,9 compounding
their psychosocial struggles with conflicting identities.27
HIV treatment in Malaysia
In Malaysia, HIV care is primarily delivered through the public Ministry of Health system which
provides no-cost care and no-cost first-line ART.28 First-line ART in Malaysia –primarily
comprised of Efavirenz, Emtricitabine, Tenofovir disoproxil – is fully covered by the
government while second-line therapy is partially subsidized.28
The HIV care continuum framework is a widely utilized model to describe and evaluate the
progress of PWH along the spectrum of engagement in HIV care.29 Steps in the care continuum
include diagnosis, linkage and retention in HIV care, initiation of ART, adherence to ART, and
viral suppression.30 Minimizing the gaps between these steps is essential for successful test-andtreat29 and treatment as prevention (TasP) strategies,31 as well as for reducing HIV-related
morality. Optimizing engagement and retention in the continuum is also necessary for patients to
achieve and maintain viral suppression.32,33
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This framework was also recognized and adopted in the Joint United Nations Programme on
HIV/AIDS’ (UNAIDS) 90-90-90 target for the year 2020: 90% of all PWH know their HIV
status, 90% of those who know their status receive sustained ART, and 90% of those receiving
ART be virally suppressed.34
While Malaysia has made progress in the scale-up of HIV testing and universal access to no-cost
ART for all Malaysian PWH,6 several areas of the care continuum remain suboptimal. As of
2019, the Ministry of Health estimated that 86% of PWH were aware of their status, while 48%
of PWH were receiving ART.2 The latest survey on ART initiation among Malaysian MSM
indicated that 13.5% were currently on treatment.7 Moreover, there is no data on the proportion
of PWH achieving HIV viral suppression for 2019 (UNAIDS reported 42% in 2018).8 It is
difficult to assess at which of these points MSM PWH are falling off because the Malaysian
Ministry of Health does not aggregate HIV care continuum results by key populations.
Linkage to HIV care, initiation and retention on ART and HIV viral suppression are key to
reducing mortality among PWH and preventing onward transmission of HIV. Given the
suboptimal outcomes for PWH in Malaysia, particularly among MSM, the present study will
evaluate the barriers and facilitators of linkage to HIV care, initiation and retention on ART, and
achievement of HIV viral suppression among a sample of newly diagnosed HIV+ MSM in
Greater Kuala Lumpur. Specifically, the study will examine the proportion of participants who
achieve each of these three steps in the HIV continuum of care.
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Methods
Participants
Participants (n = 163) were recruited using venue-based convenience sampling at the University
Malaya Medical Centre’s (UMMC) HIV clinic in Kuala Lumpur. One of the largest HIV clinics
in Malaysia, UMMC provides ongoing HIV care to approximately 1700 PWH, with an average
of 100 to 120 PWH encounters each week. Inclusion criteria were: 1) cisgender male; 2) ≥ 18
years of age; 3) screened positive for HIV in the last 6 to 60 months; 4) identify as man who has
sex with other men; 5) able to speak Bahasa Malaysia, Mandarin, or English; 6) able to provide
informed consent; and 7) willing to consent to provide a release of medical information
authorization for health records associated with their HIV care and treatment at UMMC.
Patients with appointments were pre-screened for eligibility based on their electronic medical
records and recruited during their waiting time. Walk-in patients were also reviewed for
eligibility during their visit. Study flyers were posted on the wall of exam rooms and physicians
were given study leaflets share with potentially eligible patients. Inpatient wards were also
regularly checked for study candidates.
Procedures
Following informed consent, participants were self-administered a questionnaire using a tablet or
laptop in a designated private area of the clinic. The questionnaire was programmed and
administered using Qualtrics (Qualtrics, Inc., Provo, Utah, USA) online survey software. All
study materials were translated into in English, Mandarin, and Bahasa Malaysia. All participants
were offered the opportunity to enter a drawing for a free tablet computer for their participation
in the study.
8

Measures
Structured Questionnaire
Questionnaire measures included sociodemographic factors, including age, ethnicity, primary
language, religion, country of birth, highest level of education achieved, employment status,
relationship status, monthly income, and housing status.
Lifetime and recent (last 30 days) alcohol and drug use were also measured, including alcohol,
amphetamine-type stimulants (ATS), primarily methamphetamine; ecstasy / MDMA (3,4Methylenedioxymethamphetamine); heroin or other opioids, including prescription narcotics;
cocaine; foxy,35 a synthetic tryptamine (5-methoxy-N, N-diisopropyltryptamine;35 GHB/GBL
(Gamma‐Hydroxybutyrate); marijuana; ketamine; benzodiazepines; and LSD (lysergic acid
diethylamide). Lifetime and recent (last 30 days) engagement in chemsex, defined as any use of
ATS, ecstasy / MDMA, or GHB / GBL, prior to or during sexual activity.
Participants were also asked to answer questions on their sexually transmitted infection (STI)
and HIV history, such as self-reported date of diagnosis, visit history, CD4 and HIV viral load
test information, as well as their antiretroviral therapy (ART) regimen and adherence. Other
questions were on barriers to getting HIV care such as financial cost, lack of transportation, wait
time, and employer leave policy.
Depression was assessed using the Center for Epidemiologic Studies Short Depression Scale
(CESD-10)36. The scale had a possible range of 0 to 30, and a previously validated37 cutoff score
of 10 or higher was used to classify those with severe depressive symptoms. On average, it took
participants 15 to 20 minutes to complete the survey.
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Electronic Medical Chart Review
Data collected during the chart review include: all UMMC HIV care visit encounter dates, all
CD4 count and HIV Viral Load (VL) test dates and laboratory results, date of HIV diagnosis,
date of antiretroviral treatment (ART) initiation, interruptions or changes in ART regimen,
current diagnoses, current non-ART medications, and any notable background information of the
participant recorded by the doctor.
HIV-related Measures
Several important HIV-related measures collected from the questionnaire and/or medical chart
review will be used to describe the HIV care continuum of participants. Questionnaire measures
include self-reported STI and HIV testing and diagnosis history, HIV-care visit history, CD4 and
HIV viral load laboratory test results as, and ART adherence as best as they can recall.
Participants were also asked to report social barriers to HIV care such as financial costs, wait
time, ability to leave school or work, and access to transportation.
Table 1 describes measures of the HIV care continuum extracted using responses to the
questionnaire and data from medical chart review.
Ethics and Human Subjects Protection
All participants were asked to provide consent for Release of Information (ROI) of their health
records and medical information related to their care at UMMC. This authorization was required
for participation in the study.
This study was approved by the Institutional Review Boards for Yale University and the
University of Malaya Medical Centre (UMMC).
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Statistical Analysis
Frequencies and descriptive statistics were used to characterize the participants. We used
bivariate logistic regression to examine possible sociodemographic and HIV care-related
predictors of viral non-suppression (defined as detectable load > 200 copies/mL). We ran a
multivariable logistic regression analysis using independent variables with statistical significance
at the p ≤ 0.10 level. Odds ratios with 95% confidence intervals were reported. All analyses were
conducted in IBM SPSS Statistics 26 (Chicago, IL).
Results
Description of sample
The mean age was 35.4 years (SD = 8.4). (Table 2). Over half (54.6%) were Chinese, followed
by Malay (35.0%). Buddhism (35.6%) and Islam (35.6%) were the two most popular religions.
Majority were highly educated (66.3%), with a bachelor’s degree or beyond. 80.4% had a fulltime job and the mean monthly income of the whole sample was USD 1,466.32 (SD = 1,418.93).
A little over half (54.6%) were single, divorced, or separated from their spouse. The majority
(92.7%) of this population had stable housing.
Lifetime and active substance use history are illustrated in Figure 1. Alcohol (66.3%), ATS
(33.1%), ecstasy (27.0%), and GHB (20.9%) were the most used drugs across the lifetime.
Similarly, alcohol (39.3%), ATS (11.7%), GHB (6.1%), and ecstasy (3.7%) were the most used
drugs during the previous 30 days. Opioids were among the least used drugs across the lifetime
(1.2%) and last 30 days (0.6%). Chemsex across the lifetime was reported by 39.9% of
participants, with 9.8% having engaged in chemsex in the last 30 days. Lifetime drug injection
behavior was reported by 9.2% of participants and 1.8% had injected drugs in the last 30 days.
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Lifetime STI testing and diagnosis history is depicted in Figure 2. Over half of participants
(50.9%) reported being previously diagnosed with Syphilis, with lower proportions having been
ever diagnosed with gonorrhea (13.5%), hepatitis B (11.0%), chlamydia (7.4%), and hepatitis c
(4.9%).
Of all the participants, 39.9% reported a CESD score above 10, which indicates higher levels of
depression symptoms in this group.
HIV Care Continuum
Figure 3 illustrates the proportion of study participants’ successes along the cascade of HIV care.
The majority (54.6%, Figure 4) were diagnosed in a private hospital or clinic and on average,
lived with HIV for 2.36 years (SD = 1.34). Mean time from HIV diagnosis to linkage to HIV
care among this sample was 4.14 months (SD = 8.42). In correspondence with the eligibility
criteria, 100% of this study sample has been positively diagnosed for HIV and have made at least
one HIV care visit in the last 12 months. At baseline, 11% had a viral load higher than one
million copies/mL and 30.1% had a CD4 count of less than 100. Nearly all (99.4%) self-reported
that they are on ART. On average, time from HIV diagnosis to ART initiation was 2.20 months
(SD = 3.39). Self-reports of adherence during the past 30 days were high, with levels of 94.4%,
93.8%, and 75.3% for adherence levels of 80% or more, 90% or more, and 100%, respectively.
At the <200 copies/mL cut-off level, 151 (92.6%) achieved viral suppression, while 130 (79.7%)
achieved optimal suppression at a more conservative cut-off of <20 copies/mL. A majority
(69.3%) of the sample was both virally suppressed and 100% adherent to ART the past 30 days.
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Correlates of HIV viral non-suppression
Of all the participants, only those who had at least one viral load test in the last 18 months (N =
160) were included in the final bivariate and multivariate logistic regression models. At the
bivariate level, participants who were ethnic Malay (OR = 2.83; 95% CI = 0.85 – 9.37; p =
0.089), employed less than full-time (OR = 6.89; 95% CI = 2.02 – 23.46; p = 0.002), single (OR
= 10.14; 95% CI = 1.28 – 80.6; p = 0.028), had a baseline CD4 count ≤ 100 cells/mm3 (OR =
3.65; 95% CI = 1.10 – 12.15; p = 0.035), or were initially diagnosed in a government clinic or
hospital (OR = 5.59; 95% CI = 1.59 – 19.60; p = 0.007) were significantly more likely to have a
detectable HIV viral load in the previous 18 months. Participants who were initially diagnosed in
a private clinic, however, were significant less likely to have a detectable HIV viral load in the
last 18 months (OR = 0.25; 95% CI = 0.06 – 0.95; p = 0.042). In the multivariable model, not
having a full-time job and being single were associated with viral non-suppression (viral load of
200 copies/mL or more). Those who did not have a full-time job had 6-fold higher odds of
having a detectable viral load (aOR = 6.25; 95% CI = 1.53 – 25.49; p = 0.011) compared to those
who did. Participants who reported that they were single were 9 (aOR = 9.15; CI = 1.07 – 78.21;
p = 0.043) times more likely to have a detectable viral load compared to non-single participants.
Discussion
To our knowledge, this is the first study to describe the HIV care continuum among MSM living
with HIV in Malaysia. Results showed nearly all participants were on ART (99.4%) and the
majority had achieved viral suppression (79.7% virally suppressed at <20 copies/mL) and
adherence (75.3% adherent to ART = 100%). In this sample, opportunities remain for
minimizing time between steps in the cascade. On average, there was a 4-month delay in linkage
to care and 2-month period before ART initiation. The overall level of success was likely
13

possible due to UMMC’s unique position as a quasi-public institution with more independence.
These findings may not be generalizable to all HIV-positive MSM in Malaysia, as this sample
was recruited from a clinic and already engaged in care. Future studies should sample from a
wider range of venues and include those disengaged from care.
In this study, HIV viral non-suppression was associated with unstable employment. Individuals
with employment less than full-time were more likely to have a detectable viral load than those
with full-time employment. This finding can allude to financial limitations experienced by
individuals with less than full-time employment. Previous studies have demonstrated
associations between lower socioeconomic status (SES) and worse adherence and overall
treatment outcomes38-40. Among this sample, 25.8%, 30.1%, and 14.1% said financial costs
prevented them from receiving a CD4 test, HIV viral load test, and ART, respectively. Financial
constraints could also explain why three participants did not have a viral load test within the last
18 months. For some patients at UMMC, even subsidized viral load test costs can be
burdensome.
Being single (including divorced and separated) was also independently associated with viral
non-suppression. Compared to those in relationship, single people had ten times the odds of viral
non-suppression. This aligns with other findings that social support in the form relationships has
been associated with better ART adherence41,42 and lower viral loads among MSM.43,44 These
results suggest that interventions promoting relationship and social support can benefit treatment
outcomes in HIV-positive MSM.
Additional factors associated with viral non-suppression were the location of HIV diagnosis,
CD4 count at baseline, and Malay ethnicity. These results follow that of prior studies which
found an association between lower baseline CD4 cell count and greater risk of viral
14

rebound.45,46 Baseline CD4 count has also been shown to be a better predictor of viral
suppression that baseline viral load.47 Overall, 11% and 30.1% of this group had baseline viral
loads higher than one million copies/mL and baseline CD4 counts less than 100, respectively,
indicating that many patients do not find out they are HIV-positive for a long time. The
significance of location of HIV diagnosis may be explained by participants’ financial abilities.
Private health care recipients may not experience financial barriers to seeking care compared to
their counterparts. Among our participants, 54.6% were diagnosed in a private hospital or clinic
(Figure 4).
Though not found to be statistically significant factors in viral suppression, lifetime alcohol and
substance use among this sample were fairly high (Figure 1). In particular, lifetime alcohol use
was highest at 66.3% followed by poppers (44.8%), ATS (33.1%) and ecstasy (27.0%). These
percentages drastically reduced for active use. One explanation may be that recently diagnosed
PWH engage in less transmission risk behaviors immediately after their diagnosis.48 Social
desirability bias may also be at play, with participants choosing responses that are more socially
acceptable in Malaysia.49 Future studies should test for longer windows of “active use,” from 90
days up to a year.
Despite our results, alcohol and drug use among PWH should continue to be studied for its
impact on other aspects of HIV care. This study observed higher levels of lifetime (39.9%) and
active (9.8%) chemsex participation than seen in unpublished data (lifetime = 21.8%, active =
6.2%) from a study of HIV-Syphilis co-infection among MSM in Malaysia.50 PWH who use
alcohol and drugs to cope with HIV-related stress are less likely to be adherent to ART.41,51,52
Furthermore, nearly half (39.9%) of this sample reported high levels of depression symptoms,
which has also been associated with nonadherence to ART.52,53
15

In the multivariable analysis, two covariates remained significant. Not having full-time
employment was associated with 6.25 times the odds of non-viral suppression compared with
those who did. Individuals who were single were 9.15 times more likely to be virally nonsuppressed than those in a relationship. All significant covariates in this multivariate model were
social measures, suggesting that socioeconomic statuses of HIV-positive MSM are important
parts of successful care and treatment. Clinicians should ask more non-clinical questions and
document these aspects of their patients. Future studies should incorporate social measures
beyond those included here.
There were several limitations in this study. First, these results may not be generalizable to those
who are not engaged in care or those who progressed to death without being linked to care, as
this population was recruited from a clinic. We also lacked medical chart data for participants
who may have previously received HIV care outside of UMMC. In general, quality of the data
captured through UMMC’s electronic medical records (EMR) was varied and dependent on the
physician in charge. Aside from laboratory test results, all EMR were in text form and not
standardized across patients. Critical information for some, such as HIV diagnoses and ART
initiation dates, did not match self-reported dates. Access to EMR in general was restrictive with
clinicians themselves only being able to view patient data up to 24 hours within a care visit.
Clinicians also had no access to important patient information outside of their department, such
as psychiatric comorbidities or prescriptions for other illnesses.
Conclusions
Despite these limitations, this study is the first to evaluate the HIV care continuum in MSM from
Kuala Lumpur. While these results indicate that many Malaysian HIV-positive MSM linked to
care are able to achieve viral suppression, it also highlights potential socioeconomic barriers
16

faced by this population. Future efforts should focus on evaluating other social barriers faced by
individuals linked to care.
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Appendix
Table 1. Measurement of the HIV care continuum
Variable

Source

Measurement

Definition

Linkage to HIV
care

Self-reported HIV diagnosis
on questionnaire; HIV care
visit dates from chart review

Binary (0,1)

Completion of at least
one HIV care clinic
visit within 12 months
of diagnosis

Time to linkage
to HIV care

Self-reported HIV diagnosis
on questionnaire; HIV care
visit dates from chart review

Continuous
(months)

Time (months) between
the date of self-reported
HIV diagnosis and the
completion of the first
HIV care clinic visit

Initiation of
ART

Self-reported date of
initiation of ART and
recorded initiation date on
chart review

Binary (0,1)

Initiation of ART,
defined as the patient
having started taking
ART

Time to
initiation of
ART

Self-reported date of HIV
diagnosis on questionnaire;
self-reported date of
initiation of ART and
recorded initiation date on
chart review

Continuous
(months)

Time (months) between
the date of first HIV
care clinic visit and
self-reported date of
ART initiation

Adherence to
ART

Self-reported percent of
doses completed in last 30
days on questionnaire

Self-reported
percent of doses
completed in last
30 days

Self-reported adherence
during the past 30 days
using visual analog
scale

Achievement of
HIV viral
suppression

Viral load test results on
chart review

Continuous
(copies/mL) and
binary (0,1)

Most recent HIV-RNA
test (< 18 months) = <
200 copies/mL
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Table 2. Characteristics of study population (n = 163)
Characteristic
n (%)*
Age (years), mean ± SD
35.4 years ± 8.4
Ethnicity
Malay
57 (35.0)
Chinese
89 (54.6)
Indian
9 (5.5)
Other
8 (4.9)
Religion
Buddhism
58 (35.6)
Christianity
23 (14.1)
Hinduism
5 (3.1)
Islam
58 (35.6)
None/Atheist/Agnostic
18 (11.0)
Other
1 (0.6)
Education
Less than high school
3 (1.8)
High school
52 (31.9)
Bachelor’s degree or beyond
108 (66.3)
Employment
Full Time
131 (80.4)
Part Time
13 (8.0)
Unemployed
17 (10.4)
Student
2 (1.2)
Relationship status
Single
85 (52.1)
Boyfriend/Partner
68 (41.7)
Married
6 (3.7)
Divorced or separated
4 (2.5)
from spouse
Housing
House/apartment alone
72 (44.2)
House/apartment with others
79 (48.5)
Hotel/motel/guesthouse
1 (0.6)
Other
6 (3.7)
Monthly Income (MYR), mean ± SD
6,389.63 ± 6183.11
* Percentages may not sum to 100% due to rounding.
† Housing question has missing data (n = 158) since it was a newly added question.
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Table 3. Unadjusted and adjusted associations between study variables and viral non-suppression (n = 160*)
Characteristic
Demographics
Age (years): 18 – 24
Age (years): 25 – 34
Age (years): 35+
Ethnicity: Malay
Ethnicity: Chinese
Education: Less than college
Employment: Not full time
Income (MYR): Low income, <100
Relationship Status: Single
Housing: Unstable
HIV Care-related
CD4 count at baseline: 100 cells/mm3 or less
VL at baseline: 1 million copies/mL or more
VL at baseline: 2 million copies/mL or more
Switch in ART regimen: At least once
HIV-related hospitalization: At least once
Location of HIV diagnosis: gov’t
Location of HIV diagnosis: private
Location of first care since diagnosis: gov’t
Location of first care since diagnosis: private
Vitamin training: never received
Substance Use
Lifetime: Chemsex
Lifetime: Alcohol
Lifetime: Marijuana
Lifetime: ATS
Lifetime: Ecstasy (E, MDMA)
Lifetime: “Club” drugs ‡

n (%)†

Unadjusted OR
(95% CI)

p

10 (6.2)
77 (47.2)
74 (45.4)
57 (35.0)
89 (54.6)
55 (33.7)
32 (19.6)
15 (9.2)
89 (54.6)
7 (4.3)

1.38 (0.16, 11.94)
0.76 (0.23, 2.49)
1.21 (0.37, 3.94)
2.83 (0.85, 9.37)
0.58 (0.17, 1.90)
2.08 (0.64, 6.80)
6.89 (2.02, 23.46)
2.08 (0.41, 10.51)
10.14 (1.28, 80.6)
2.08 (0.23, 18.82)

0.768
0.643
0.749
0.089
0.363
0.224
0.002
0.377
0.028
0.516

50 (30.7)
18 (11.0)
8 (4.9)
40 (24.5)
4 (2.5)
49 (30.1)
89 (54.6)
48 (29.4)
31 (19.0)
10 (6.1)

3.65 (1.10, 12.16)
2.93 (0.72, 12.03)
0.0 (0.0, 0.0)
0.67 (0.14, 3.23)
0.0 (0.0, 0.0)
5.59 (1.59, 19.60)
0.25 (0.06, 0.95)
1.05 (0.25, 4.38)
2.02 (0.47, 8.59)
3.50 (0.65, 18.72)

0.035
0.135
0.999
0.614
0.999
0.007
0.042
0.951
0.342
0.143

65 (39.9)
108 (66.3)
33 (20.2)
54 (33.1)
44 (27.0)
68 (41.7)

0.71 (0.21, 2.47)
1.02 (0.29, 3.55)
0.33 (0.04, 2.65)
0.98 (0.28, 3.41)
0.52 (0.11, 2.49)
0.68 (0.20, 2.34)

0.594
0.975
0.297
0.975
0.414
0.535

Adjusted OR
(95% CI)

p

2.94 (0.73, 11.84)

0.130

6.25 (1.53, 25.49)

0.011

9.15 (1.07, 78.21)

0.043

1.82 (0.45, 7.29)

0.400

0.40 (0.09, 1.76)

0.226
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Active: Chemsex
16 (9.8)
0.81 (0.10, 6.69)
0.842
Active (last 30 days): Alcohol
64 (39.3)
0.50 (0.13, 1.94)
0.317
Active (last 30 days): Marijuana
5 (3.1)
0.0 (0.0, 0.0)
0.999
Active (last 30 days): ATS
19 (11.7)
0.66 (0.08, 5.39)
0.695
Active (last 30 days): Ecstasy (E, MDMA)
6 (3.7)
0.0 (0.0, 0.0)
0.999
Active (last 30 days): “Club” drugs
20 (12.3)
0.66 (0.08, 5.39)
0.695
Depression (CES-D score above 10)
65 (39.9)
1.11 (0.34, 3.66)
0.866
*Key: OR = odds ratio; aOR = adjusted odds ratio; ATS = Amphetamine-type stimulants; E = Ecstasy; MDMA = 3,4-Methylenedioxy
methamphetamine; CES-D = Center for Epidemiological Studies Depression Scale.
†
Three cases whose most recent viral load test was > 18 months were removed.
‡
Number of cases for each variable may not sum to total number of participants due to missing values.
§
“Club” drugs include methamphetamine, Ecstasy (E, MDMA), GHB, Ketamine.
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Figure 1. Lifetime and active substance abuse history (n = 163)

ATS = amphetamine-type stimulants; GHB = gamma hydroxybutyrate; LSD = lysergic acid diethylamide
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Figure 2. STI testing and diagnosis history (n = 163)
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Figure 3. The HIV care continuum among recently diagnosed HIV-positive men who have sex with men in Kuala Lumpur,
Malaysia (n = 163)
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Figure 4. Location of HIV diagnosis (n = 163)
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